drugset
drugset / Trial / NCT06181084

A Study Comparing Different Formulations of LY3410738 in Healthy Adult Participants

NCT06181084 ↗

Phase 1 Completed 60 enrolled Eli Lilly and Company Loxo Oncology, Inc. · collab
RandomizedCrossoverOpen-labelBasic science

Summary

The main purpose of study is to compare different formulations of LY3410738 under fasting condition by looking at the amount of the study drug, LY3410738, that gets into the blood stream and how long it takes the body to get rid of it when given in healthy adult participants. The study will also access the effect of standard low-fat meal and esomeprazole (Proton Pump Inhibitor) on LY3410738. Safety and tolerability of LY3410738 will also be evaluated. For each participant, the total duration of the study will be 56 days for Groups 1 and 2 and up to 61 days for Groups 3 and 4, including screening.

Timeline

Start
2021-10-11
Primary completion
2022-04-28
Completion
2022-04-28

Drugs

EvaluationDrugModalityDoseRoute
Subject CRELOSIDENIB Small molecule — Oral
Background Esomeprazole Small molecule — Oral

Indications

No indication recorded.